Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
$48.31
+0.6%
$52.22
$21.34
$58.40
$3.86B-0.281.42 million shs838,999 shs
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$109.39
+4.0%
$105.69
$75.56
$139.13
$5.46B0.51781,630 shs589,197 shs
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
$31.55
+5.2%
$34.23
$27.66
$121.06
$4.10B1.211.80 million shs2.64 million shs
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$18.05
+3.7%
$15.53
$8.46
$25.29
$1.61B0.741.65 million shs1.65 million shs
5G Stocks: The Path Forward is Profitable Cover

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-0.52%-3.09%-6.86%+26.80%+98.55%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+1.22%+1.58%-3.44%+1.50%+23.92%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
+1.11%-11.06%-16.50%+1.97%-61.59%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
+0.75%+4.38%+5.71%-17.45%+98.97%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
4.0961 of 5 stars
3.53.00.04.73.30.80.0
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
4.8293 of 5 stars
4.53.00.04.52.44.20.6
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
2.0119 of 5 stars
3.52.00.00.02.31.70.0
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.0508 of 5 stars
3.41.00.00.03.30.80.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3.00
Buy$81.5768.85% Upside
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
3.07
Buy$178.0062.72% Upside
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.09
Buy$136.50332.65% Upside
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
2.87
Moderate Buy$32.2178.47% Upside

Current Analyst Ratings Breakdown

Latest TVTX, AXSM, AKRO, and PCVX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
8/7/2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$30.00 ➝ $31.00
8/7/2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$30.00 ➝ $32.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$173.00 ➝ $176.00
8/5/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$184.00 ➝ $189.00
8/4/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy
8/4/2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$76.00
8/4/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$150.00
7/3/2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$190.00
(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/A$12.82 per shareN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$495.03M11.03N/AN/A$1.46 per share74.92
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/A$23.66 per shareN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
$233.18M6.90N/AN/A$0.37 per share48.78
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$287.22M-$5.07N/A38.79N/A-49.88%-283.22%-33.06%N/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$463.93M-$4.11N/AN/AN/AN/A-16.85%-15.92%N/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$321.55M-$2.04N/AN/AN/A-50.64%-717.68%-30.69%10/30/2025 (Estimated)

Latest TVTX, AXSM, AKRO, and PCVX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/8/2025Q2 2025
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
-$0.97-$0.86+$0.11-$0.86N/AN/A
8/6/2025Q2 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.12-$1.22-$0.10-$1.22N/AN/A
8/6/2025Q2 2025
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
-$0.28-$0.14+$0.14-$0.14$100.18 million$94.84 million
8/4/2025Q2 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$1.00-$0.92+$0.08-$0.97$140.02 million$150.04 million
5/14/2025Q1 2025
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
-$1.02-$1.04-$0.02-$1.04N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/AN/AN/AN/AN/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/AN/AN/AN/AN/A
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
0.02
12.66
16.80
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.66
1.57
1.51
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
N/A
11.11
11.11
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
9.50
2.00
1.98

Institutional Ownership

CompanyInstitutional Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
N/A
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
96.78%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
N/A

Insider Ownership

CompanyInsider Ownership
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
7.07%
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
22.40%
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
3.10%
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
4.06%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akero Therapeutics, Inc. stock logo
AKRO
Akero Therapeutics
3079.99 million74.08 millionOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38049.90 million38.72 millionOptionable
Vaxcyte, Inc. stock logo
PCVX
Vaxcyte
160129.82 million125.80 millionOptionable
Travere Therapeutics, Inc. stock logo
TVTX
Travere Therapeutics
46089.14 million85.52 millionOptionable

Recent News About These Companies

TVTX FY2025 EPS Forecast Boosted by Cantor Fitzgerald
Cantor Fitzgerald Issues Positive Outlook for TVTX Earnings
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $31.00
Earnings Preview: Travere Therapeutics

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akero Therapeutics stock logo

Akero Therapeutics NASDAQ:AKRO

$48.31 +0.28 (+0.58%)
Closing price 04:00 PM Eastern
Extended Trading
$48.15 -0.16 (-0.33%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$109.39 +4.16 (+3.95%)
Closing price 04:00 PM Eastern
Extended Trading
$108.23 -1.16 (-1.06%)
As of 05:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Vaxcyte stock logo

Vaxcyte NASDAQ:PCVX

$31.55 +1.55 (+5.17%)
Closing price 04:00 PM Eastern
Extended Trading
$32.12 +0.57 (+1.79%)
As of 06:11 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

Travere Therapeutics stock logo

Travere Therapeutics NASDAQ:TVTX

$18.05 +0.64 (+3.68%)
Closing price 04:00 PM Eastern
Extended Trading
$18.06 +0.01 (+0.06%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones. The company's clinical-stage programs consist of Sparsentan, a novel investigational product candidate, which has been granted Orphan Drug Designation for the treatment of focal segmental glomerulosclerosis in the U.S. and Europe; and Pegtibatinase (TVT-058), a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.